The interplay between an evolving cancer and a dynamic immune microenvironment remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and histopathologyassessed tumour-infiltrating lymphocyte estimates. Immune infiltration varied both between and within tumours, with different mechanisms of neoantigen presentation dysfunction enriched in distinct immune microenvironments. Sparsely infiltrated tumours exhibited a waning of neoantigen editing during tumour evolution, indicative of historical immune editing, or copy-number loss of previously clonal neoantigens. Immune-infiltrated tumour regions exhibited ongoing immunoediting, with either loss of heterozygosity in human leukocyte antigens or depletion of expressed neoantigens. We identified promoter hypermethylation of genes that contain neoantigenic mutations as an epigenetic mechanism of immunoediting. Our results suggest that the immune microenvironment exerts a strong selection pressure in early-stage, untreated non-small-cell lung cancers that produces multiple routes to immune evasion, which are clinically relevant and forecast poor disease-free survival.
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Anti-tumour immune responses require the functional presentation of tumour antigens and a microenvironment that is replete with competent immune effectors 1,2 . However, the extent to which an active immune system sculpts the evolution of the tumour genome in untreated early-stage tumours has not been well characterized. Although associations between immune infiltration and tumour clonal diversity have previously been observed in some contexts 3, 4 , whether the immune system acts as a dominant selective force in early-stage untreated cancer is unclear. Both genetic and transcriptomic heterogeneity might confound conclusions drawn from sampling a single tumour sample, leading to inaccurate interpretations of mechanisms of immune evasion.
To determine immune infiltration in untreated non-small-cell lung cancer (NSCLC), assess how this infiltration varies between and within tumours, and characterize immune-evasion mechanisms and their associations with clinical outcome, we integrated 164 RNA-sequencing (RNA-seq) samples from 64 tumours and 234 tumour-infiltrating lymphocyte (TIL) histopathology estimates (hereafter, pathology TIL estimates) from 83 tumours to produce a combined cohort of 258 tumour regions from 88 prospectively acquired tumours within the 'Tracking Non-Small-Cell Lung Cancer Evolution through Therapy' (TRACERx) 100 cohort 5 . We explored how selection pressures from a diverse tumour microenvironment affect neoantigen presentation, as well as tumour-intrinsic mechanisms that lead to immune escape and their respective effects on clinical outcomes.
Heterogeneity of immune infiltration
We benchmarked published in silico immune deconvolution tools (Methods) to estimate immune infiltration in the multi-region NSCLC TRACERx RNA-seq cohort. Compared to other transcriptomic approaches [6] [7] [8] [9] [10] , the Danaher et al. 11 immune signature optimally estimated immune infiltrates in NSCLC (Extended Data Fig. 1 ).
Using this approach, we estimated RNA-seq-derived infiltrating immune cell populations for the 164 tumour regions from 64 patients in the TRACERx 100 cohort 5 , for which there was RNA of sufficient quality (Extended Data Fig. 2a , b, Supplementary Table 1) .
A wide range in the extent of immune infiltration was observed between and within histologies (Extended Data Fig. 3 ), as well as between separate regions from the same tumour. Unsupervised hierarchical clustering revealed two distinct immune clusters for each histology, which corresponded to high and low levels of immune infiltration. Individual tumour regions were stratified as having either high or low levels of immune infiltrate (Fig. 1) .
Consistent with our clustering approach, tumour regions with high levels of immune infiltration contained higher pathology TIL estimates as compared to regions with low levels of immune infiltration
Article reSeArcH (P = 3 × 10 −5 ) (Extended Data Fig. 4a ). Owing to the strong correlation that we observed between RNA-seq-derived immune estimates and pathology TIL estimates (Extended Data Fig. 1e ), we also used pathology TIL estimates to group tumour regions for which RNA-seq data were not available (Extended Data Fig. 4b , c, Methods). The predicted abundance of myeloid-derived suppressor cells and tumourassociated M2 macrophages 12 negatively correlated with the immune activating-cell subsets (Extended Data Fig. 4d , e), which indicates that immunosuppressive cells may influence the immune microenvironment. Eleven per cent of tumour regions-mostly of lung adenocarcinomahad pathology TIL estimates that were not reflected in the immune cluster to which they were assigned by RNA-seq, which potentially reflects a heterogeneity of sampling due to spatial variation in the mirrored tissue samples used to score TILs and extract RNA.
Overall, 63 patients had tumours with uniformly low (38 tumours (43%)) or high (25 tumours (28%)) levels of immune infiltration, and 25 patients had tumours with disparate levels of immune infiltration between tumour regions (28%) (Extended Data Fig. 4c ). We also found that intratumour heterogeneity confounded genomic and transcriptomic biomarkers that are used for the prediction of response to immune-checkpoint blockade. For example, the TIDE 12 classifier was heterogeneous in 17 out of 42 tumours (Extended Data Fig. 5a ), and heterogeneously infiltrated tumours tended to exhibit a heterogeneous TIDE signature (P = 0.05) (Extended Data Fig. 5a ). Likewise, a transcriptomic signature predicting innate resistance to PD-1 immune checkpoint blockade (IPRES) 13 and an IFN-signalling score 14 were also heterogeneous (Extended Data Fig. 5b-d) . In a recent prospective study, high mutation burden (>10 mutations per megabase) was found to be associated with an improved response to immunotherapy 15 . Twelve out of fifty-seven (21%) NSCLCs with a high mutation burden had at least one tumour region that contained a low mutation burden (Extended Data Fig. 5e ). Heterogeneously infiltrated tumours were also more likely to exhibit a heterogeneous tumour mutation burden (P = 7 × 10 −4 ) (Extended Data Fig. 5f ). Among tumours with a heterogeneous tumour mutation burden, the regions with a low mutation burden had significantly lower tumour purity than regions with a high mutation burden, which indicates that it is important to consider tumour stromal content as a confounding factor to mutation burden assessment (paired t-test, P = 0.04) (Extended Data Fig. 4f ).
Immune infiltration and tumour evolution
We calculated a distance measure in genomic and immune space for all pairwise combinations of tumour regions from the same tumour to explore the relationship between tumour genomic features and the immune microenvironment (Methods). We observed a significant correlation between the two pairwise distance measures (Fig. 2a , lung adenocarcinoma, P = 3.5 × 10 ; lung squamous cell carcinoma, P = 2 × 10
−3
). We observed a similar relationship when comparing the pairwise immune and copy-number alteration distances, which reached statistical significance among the lung adenocarcinoma cohort (Extended Data Fig. 6a ). These results support an interplay between the immune and cancer genomic landscape and that tumour regions distant in genomic space have distinct immune microenvironments.
To further explore this interplay, we considered the relationship between the clonal structure of each tumour region and its immune infiltrate. We compared CD8 + T cell infiltration estimated from RNA-seq data to within-region subclonal diversity (Shannon diversity; see Methods). A significant negative correlation was observed in lung adenocarcinoma but not squamous cell carcinoma; regions with high CD8 + T cell infiltration had lower subclonal diversity (lung If all the regions of a patient's tumour are classified as having low levels of immune infiltration, the patient is indicated in blue. If all the regions of a patient's tumour are classified as having high levels of immune infiltration, the patient is indicated in red. Patients who have tumours that contain heterogeneous levels of immune infiltration are indicated in orange. An example pathology image from a heterogeneous tumour is shown below each heat map to display a region with a high level of immune infiltration and a region with a low level of immune infiltration from the same tumour.
Article reSeArcH adenocarcinoma, P = 0.035, ρ = −0.22; lung squamous cell carcinoma, P = 0.91, ρ = −0.02) (Extended Data Fig. 6b, c) . Lung adenocarcinoma regions from tumours with uniformly low levels of immune infiltration exhibited greater subclonal diversity when compared to regions from tumours with high or heterogeneous levels of immune infiltration ( Fig. 2b, c ; lung adenocarcinoma, P = 0.01). Consistent with previous findings 3 , when pathology TIL estimates (which did not correlate with tumour purity, Extended Data Fig. 6d ) were used to stratify patients, we again observed a reduction in tumour diversity in regions from tumours with a high or heterogeneous level of TILs present (Extended Data Fig. 6e , P = 0.02).
Immune editing and the immune microenvironment
If T-cell-mediated immune surveillance of neoantigens influences the evolution of cancer genomes, one would predict neoantigen depletion and/or disruption to the antigen-presenting machinery in tumours as mechanisms of immune escape 16 . Conceivably, neoantigen depletion may occur at the DNA level (through events such as copy-number loss), at the RNA level (through the suppression of transcripts that contain neoantigens), at the epigenetic level (through the silencing of genomic segments that encode neoantigens) or through post-translational mechanisms. Alternatively, tumour subclones that express neoantigens may be preferentially eliminated by the immune system through purifying selection removing subclones containing neoantigens.
We predicted neoantigens and their clonal status to investigate neoantigen depletion. Neoantigens were defined as peptides with a predicted binding affinity < 500 nM or a rank percentage score < 2%; strong neoantigens were defined as those with a predicted binding affinity < 50 nM or a rank percentage score < 0.5% 17 (Methods). We used a published method to quantify the extent of DNA immunoediting in each tumour sample 16 . This method compares the observed and expected numbers of neoantigens present in a tumour, such that a score of <1 suggests DNA immunoediting has occurred. We found no significant difference between the observed-to-expected ratio of neoantigens in lung adenocarcinomas and lung squamous cell carcinomas (Extended Data Fig. 6f ). But we note that this score depends on the number of heterozygous human leukocyte antigen (HLA) alleles in the patient germline (P = 2.1 × 10 −5 , ρ = 0.43) (Extended Data Fig. 6g ): if fewer unique HLA types are present, there will be fewer observed neoantigens. To mitigate this bias, we investigated whether this measure changed during tumour evolution, from clonal to subclonal events within each tumour. Among tumours with a low level of infiltrate, a decrease in DNA immunoediting (that is, an increase in ratio of observed-to-expected neoantigens) was noted from clonal −4 , n = 217; lung squamous cell carcinoma, P = 0.002, n = 186). b, c, The Shannon diversity index for each tumour region is shown, grouped by immune classification. Lung adenocarcinomas (n = 159) (b) and lung squamous cell carcinomas (n = 103) (c) are shown. The minimum and maximum are indicated by the extreme points of the box plot; the median is indicated by the thick horizontal line; and the first and third quartiles are indicated by box edges. A two-sided Wilcoxon rank-sum test is used. Hetero, heterogeneous. d, The change in the observed:expected immunoediting score from clonal (C) to subclonal (S) is shown for each immune classification (high, n = 24; heterogeneous, n = 25; low, n = 33). A two-sided paired t-test is used. e, Example of loss of historically clonal neoantigens (neo) by subclonal copy-number (CN) event. Neoantigens that are present in sample CRUK0071:R3 on one copy are shown in one panel (black). These neoantigens are lost in CRUK0071:R6 (red). f, Top, the number of historically clonal neoantigens (neo) on a region of copy-number loss are shown per tumour. Bottom, the proportion of clonal neoantigens lost subclonally through a copy-number event. g, The odds ratio and 95% confidence interval of copy-number neoantigen depletion is shown, calculated with Fisher's exact test. Values >1 indicate neoantigens are more likely to be in regions of subclonal copy-number loss as compared to non-synonymous mutations that are not neoantigens. Tumour regions are classified by immune cluster. h, The change in immunoediting score is shown for tumours with low levels of immune infiltration, according to whether any neoantigens are subclonally lost through copy-number events (copy-number loss, n = 17; no copy-number loss, n = 16). A two-sided paired t-test is used. No corrections were made for multiple comparisons.
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to subclonal mutations (P = 8.8 × 10 , paired t-test) (Fig. 2d) , which possibly reflects an ancestral immune-active microenvironment that has subsequently become cold.
Neoantigen depletion may also occur at the DNA level through copy-number loss 18 ( Fig. 2e) . Across this cohort, 43 out of 88 tumours showed evidence for at least one historically clonal neoantigen being subclonally lost owing to subclonal copy-number events (Fig. 2f , range 0-42% of clonal neoantigens).
To determine whether the elimination of historically clonal neoantigens through copy-number loss occurred more frequently than expected by chance, we compared neoantigens with nonneoantigenic, non-synonymous mutations. In tumour regions with low levels of immune infiltration, non-synonymous mutations that were predicted to be neoantigens were more likely to occur on genomic segments that were subject to subclonal copy-number loss, as compared to their non-neoantigenic counterparts (P = 1.2 × 10 −4 ) (Fig. 2g) . In tumours with low levels of infiltration, reduced immunoediting of subclones was observed more frequently in tumours without evidence of neoantigen copy-number loss, which supports the role of copy-number loss as a mechanism of subclonal immunoediting (P = 0.88 versus P = 2.2 × 10 −4 ) (Fig. 2h) .
Repression of neoantigenic transcripts
We next determined whether each neoantigen was identified at the transcript level to investigate alternative neoantigen-depletion mechanisms. Overall, only 33% of clonal neoantigens were expressed in every tumour region within a given tumour; we observed a significantly lower proportion of ubiquitously expressed clonal neoantigens among tumours with high (median, 29%) or heterogeneous (median, 35%) levels of immune infiltration, as compared to tumours with low levels of immune infiltration (median, 41%) (Fig. 3a , b) (P = 0.01). To further investigate whether the downregulation of neoantigenic transcripts reflects likely immune selection pressure, we considered whether neoantigens were preferentially subject to reduction in expression as compared to non-neoantigens, an approach that is not confounded by the influence of tumour purity.
At the cohort level, tumours with intact HLA alleles exhibited a significant reduction of expressed neoantigens, as compared to nonneoantigenic, non-synonymous mutations ( Fig. 3c , P = 0.01). Moreover, when tumours were divided by immune classification, only tumours with intact HLA alleles and with high or heterogeneous levels of immune infiltration showed a depletion of expressed neoantigens, which suggests that subclones in immune-infiltrated tumours may be selected for either through HLA loss-of-heterozygosity (LOH) or through repression of neoantigen expression permitting immune evasion (Fig. 3c) . Among tumours without HLA LOH and with high levels of immune infiltration, diminished neoantigen expression was more pronounced when we used the more-stringent definition of strongly binding neoantigens (Extended Data Fig. 6h ).
Next we investigated whether there was evidence for negative selection of clones that contain expressed neoantigens. We observed an enrichment of neoantigens in genes that were expressed at a low level in the tumour sample (≤1 transcript per million), as compared to non-synonymous non-neoantigens (P = 5.5 × 10 −10 , odds ratio = 1.3) (Extended Data Fig. 6i ). This enrichment was more pronounced when we considered only strong neoantigens (P = 6.8 × 10 −13 , odds ratio = 1.4) (Extended Data Fig. 6i ). Neoantigens identified in TRACERx were also less likely to occur in genes that were consistently expressed across 1,019 NSCLC samples from The Cancer Genome Atlas (TCGA) (Fig. 3d) , as compared to non-synonymous predicted non-neoantigens (Methods). In genes that are consistently expressed in TCGA samples, the generation of neoantigenic mutations in the TRACERx cohort was most reduced among tumours with high levels of immune infiltration (P = 2.1 × 10 −4
, odds ratio = 0.77); however, we also observe this reduction among tumours with low (P = 1.8 × 10 −3 , odds ratio = 0.82) or heterogeneous (P = 0.04, odds ratio = 0.88) levels of infiltration. This is consistent with tumours with low levels of immune infiltration having once been subject to the selective pressures of an active immune microenvironment (Fig. 3d) .
To investigate the methylation status of neoantigens as a mechanism of neoantigen repression, we performed multi-region reducedrepresentation bisulfite sequencing (RRBS) (Methods) on 79 out of the 164 tumour samples (28 out of 64 patients) in the TRACERx RNA-seq cohort, in addition to adjacent normal tissue (Fig. 3e, Supplementary  Table 2 ). Among genes that carry neoantigenic mutations, an 11.4-fold shown. Bottom, the fraction of clonal neoantigens that are ubiquitously expressed. The immune class is provided as high (red), low (blue) or heterogeneous (orange). b, The fraction of clonal neoantigens that are ubiquitously expressed in every region is plotted by immune classification of the tumour (n = 63). The minimum and maximum are indicated by the extreme points of the box plot; the median is indicated by the thick horizontal line; and the first and third quartiles are indicated by box edges. A two-sided Wilcoxon rank-sum test is used. c, The odds ratio and 95% confidence interval of transcriptional neoantigen depletion is shown, calculated with Fisher's exact test. Values <1 indicate that putative neoantigens are less likely to be expressed, as compared to nonsynonymous mutations that are not putative neoantigens. Tumours are plotted by HLA LOH status and immune classification. d, The odds ratio and 95% confidence interval of a neoantigen occurring in a gene that is consistently expressed among TCGA NSCLC tumours is shown, calculated with Fisher's exact test. e, CpG methylation patterns across the LAMB1 promoter in tumour samples CRUK0057:R1 and CRUK0002:R1, and their matched normal tissues. The locus encodes two non-expressed neoantigens and exhibits hypermethylation in CRUK0057:R1. The purity-and ploidymatched non-mutated control sample CRUK0002:R1 shows no differential methylation. f-h, Numbers of (non)-hypermethylated gene promoters for expressed versus non-expressed neoantigens (f), non-expressed neoantigens versus the same genes in purity-and ploidy-matched controls (g) and expressed neoantigens versus the same genes in purity-and ploidymatched controls (h). Odds ratios (OR) and P values (χ 2 test) are shown for each comparison. No corrections were made for multiple comparisons. increase in promoter hypermethylation was observed for genes that were not expressed as compared to genes that were expressed (χ 2 test, P = 1.6 × 10 −4 ) ( Fig. 3f) . To determine whether the observed downregulation was neoantigen-specific, we compared promoter hypermethylation between all neoantigens and the same genes without the neoantigen, in samples matched for purity and ploidy. Overall, nonexpressed neoantigens were more likely to exhibit promoter hypermethylation than the same genes without a neoantigen (χ 2 test, P = 0.045, odds ratio = 2.3) (Fig. 3g, Supplementary Table 3 ). Among expressed neoantigens, we observed no difference in promoter hypermethylation state as compared to non-mutated samples matched for purity and ploidy (χ 2 test, P = 0.67, odds ratio = 0.48) (Fig. 3h , Supplementary Table 4 ). These findings suggest that immune pressures may select for promoter hypermethylation and neoantigen silencing in evolving subclones.
Pervasive disruption to antigen presentation
Defects in antigen presentation that interrupt tumour antigen recognition 19, 20 may provide another immune-evasion mechanism. To understand the importance of these avenues of immune escape in the treatment-naive setting, we mapped their occurrence region by region ( Disruptions to antigen presentation-through HLA LOH or through mutations that affect the stability of the major histocompatibility complex (MHC), the HLA enhanceosome and peptide generationwere frequently observed in both lung histologies (56% of lung adenocarcinomas and 78% of lung squamous cell carcinomas). HLA LOH and alterations that affect other components of the antigen presentation machinery (Methods), including B2M mutations, had a tendency to be mutually exclusive (lung adenocarcinoma, P = 9.3 × 10 −4 ; lung squamous cell carcinoma, P = 0.015), which supports the notion that dysfunction in antigen presentation can act as a potent immune-escape mechanism. Moreover, consistent with previous findings 20 , highly infiltrated regions of lung adenocarcinoma tumours were prone to HLA LOH (P = 3 × 10 −3 , odds ratio = 2.4). Loss of HLA-C in particular may result in the loss of the killer-cell immunoglobulin-like receptor signal that inhibits elimination through the activity of natural killer cells 21 . There are two groups of HLA-C alleles (HLA-C1 and HLA-C2), each of which has a different specificity to the killer-cell immunoglobulin-like receptor 22 . Thus, tumour cells from heterozygous patients (HLA-C1 and HLA-C2) would be expected to be targeted for elimination mediated by natural killer cells following loss of either of the HLA-C alleles (Extended Data Fig. 7b ). Conversely, tumour cells from patients with homozygous HLA-C alleles may avoid elimination mediated by natural killer cells. Consistent with this, infiltration by natural killer cells was increased in tumour regions that were heterozygous for HLA-C1 and HLA-C2 following HLA-C LOH (P = 6.2 × 10 −7 ) (Extended Data Fig. 7c ). Increased infiltration by natural killer cells was not observed among tumours that had not undergone HLA-C LOH (P = 0.12), which suggests that this change in the tumour microenvironment results from loss of the HLA-C inhibitory 'self ' signal.
Immune-evasion capacity is prognostic in NSCLC
Finally, we examined whether combining estimates of immune infiltration with immune-escape mechanisms that could be quantified For all survival curves, the number of patients in each group for every time point is indicated below the time point, and significance is determined using a two-sided log-rank test.
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at the patient level could provide prognostic power. Tumours were classified as exhibiting a low capacity for immune evasion (uniformly high levels of immune infiltration or no evidence of immune evasion (DNA immunoediting score > 1 and no disruption of antigen presentation)) or high capacity for immune evasion (at least one region with low levels of immune infiltration as well as defective antigen presentation or DNA immunoediting score < 1). Patients whose tumours had a low immune-evasion capacity had significantly longer disease-free survival (P = 9.0 × 10 −4 ) (Fig. 4c) . To explore these results in the context of previous findings that relate to the importance of clonal neoantigens 23 , we also grouped patients into two groups (high versus low clonal neoantigen burden), defined as upper quartile of cohort versus lower quartiles, as done previously 23 . Consistent with previous results, a high clonal neoantigen burden was associated with increased disease-free survival among lung adenocarcinoma (P = 0.022) and also among lung squamous cell carcinoma (P = 0.025) (Extended Data Fig. 8a ). The association that we observed between clonal neoantigens and disease-free survival was not dependent on the specific threshold used (Extended Data Fig. 8b) , and clonal neoantigen burden remained significant in a multivariate model that included stage, histology, age, gender, pack years and adjuvant therapy (P = 0.02). Conversely, no significant relationship between subclonal neoantigen burden or total neoantigen burden and disease-free survival was observed (Extended Data Fig. 8c-e) .
However, when we focused on tumours with a low clonal neoantigen load, the immune-evasion capacity of a tumour was still prognostic (P = 5.3 × 10 −3 ), which indicates that in the absence of immune evasion even a low clonal neoantigen burden may be sufficient to elicit an effective immune response (Fig. 4d) .
Furthermore, we observed that tumours with either a high clonal neoantigen load or low immune-evasion capacity exhibited significantly increased disease-free survival (P = 4.9 × 10 −6 ) (Fig. 4e ). This association remained significant in a multivariate model that included stage, histology, age, gender, pack years and adjuvant therapy (P < 0.001) (Extended Data Fig. 8f ). These data suggest that it is important to consider the many facets of the interaction between the tumour and immune microenvironment when predicting clinical outcomes.
Discussion
To capture the complex interplay between cancer genomic evolution and anti-tumour immunity in lung cancer, we integrated genomic, transcriptomic, epigenomic, and pathologic data to define how tumours are sculpted by the immune microenvironment, and to investigate which mechanisms of immune escape influence tumour evolution, as well as the relationships of active tumour-immune interactions with clinical outcome. Our results suggest the immune microenvironment is highly variable between and within patients and can be markedly different between distinct regions of the same tumour-nearly a third of the tumours we studied exhibited diverse levels of immune infiltration.
Our results provide evidence that tumour evolution is shaped through immunoediting mechanisms that affect either antigen presentation or neoantigenic mutations themselves, at both the DNA and RNA level.
Consistent with disruption to the antigen presentation machinery being subject to strong positive selection 24 , we found HLA LOH tended towards being mutually exclusive with other forms of disruption of antigen presentation such as mutations that affect MHC stability, the HLA enhanceosome or peptide generation. At the DNA level, sparsely infiltrated tumours were enriched for the elimination of clonal neoantigens, which indicates the importance of chromosomal instability in driving loss of neoantigens.
As a whole, tumours exhibited fewer neoantigens in expressed genes than expected, which potentially reflects an historical purifying selection of neoantigens. Tumours with high levels of immune infiltration and intact HLA alleles also displayed transcriptomic neoantigen depletion, which suggests that these tumours may evade immune elimination either through HLA LOH or by suppressing neoantigen expression-but seldom both. We identify promoter hypermethylation as a potential mechanism of transcriptomic neoantigen depletion that leads to the preferential repression of genes that contain neoantigenic mutations. Promoter hypermethylation affected neoantigen expression in about 23% of the neoantigens we studied, which indicates that additional mechanisms of neoantigen transcription repression await elucidation.
Through the combination of immune microenvironment and tumour immune-escape factors, we defined an estimate of the immune-evasion capacity of each tumour; high immune-evasion capactiy was associated with poorer clinical outcome. As TRACERx is a prospective study of early-stage untreated NSCLC, it will be important to validate these findings in the extended longitudinal cohort as the study matures.
The observation that clonal neoantigens can be subject to copynumber loss and transcript repression, even in untreated early-stage disease, may have important implications for predicting response and resistance to immune-checkpoint blockade. It has previously been shown that, after checkpoint blockade therapy, clonal neoantigens have been eliminated from relapse samples, which reshapes the T cell receptor repertoire of these samples 18 . Clonal neoantigens that occur in expressed genes that are required for lung cancer cell fitness may make ideal targets for vaccine or adoptive cell therapies.
The extent to which neoantigen transcript depletion is dynamic in response to therapy and tumour dissemination, and whether such phenomena may be harnessed to improve responses to immunotherapy, is unknown. Epigenetic immune evasion supports the potential for epigenetic modulatory agents, in combination with immunotherapy, to restore or improve tumour immunogenicity 25 . One possibility is that epigenetic repression of a neoantigen in a lung-cancer-expressed gene may result in a fitness cost. This may shed light on recent phenomena observed in tumours with acquired resistance to checkpoint inhibitor therapy that respond a second time upon re-challenge with the same drug 26 .
Our results suggest that early-stage, untreated NSCLCs are frequently characterized by multiple independent mechanisms of immune evasion within individual tumours, which emphasizes the strong selection pressures that the immune system imposes upon tumour evolution. Our results suggest that the beneficial role of successful immune surveillance, and the diversity of immune-evasion mechanisms, should be considered and harnessed in immunotherapeutic interventions.
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METhodS
The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Patients and samples. The cohort evaluated in this study comes from the first 100 patients prospectively analysed by the lung TRACERx study (https://clinical trials.gov/ct2/show/NCT01888601, approved by an independent research ethics committee, 13/LO/1546) and mirrors the previously described prospective 100 patient cohort 5 . Informed consent for entry into the TRACERx study was mandatory and obtained from every patient. There were 68 male and 32 female patients with NSCLC in the TRACERx study, with a median age of 68. The cohort is predominantly early-stage: Ia (26), Ib (36), IIa (13), IIb (11), IIIa (13) and IIIb (1). Seventytwo had no adjuvant treatment and 28 had adjuvant therapy. All patients were assigned a study identity number that was known to the patient. These were subsequently converted to linked study identities such that the patients could not identify themselves in study publications. All human samples (tissue and blood) were linked to the study identity number and barcoded such that they were anonymized and tracked on a centralized database, which was overseen by the study sponsor only. TRACERx 100 RNA-seq. RNA was extracted from the TRACERx 100 cohort using a modification of the AllPrep kit (Qiagen), as previously described 5 . RNA integrity was assessed by TapeStation (Agilent Technologies). Samples that had a RNA integrity score ≥ 5 were sent to the Oxford Genomics Centre for whole-RNA (RiboZero depleted) paired-end sequencing. The ribo-depleted fraction was selected from the total RNA provided, before conversion to cDNA. Second-strand cDNA synthesis incorporated dUTP. The cDNA was end-repaired, A-tailed and adaptor-ligated. Before amplification, samples underwent uridine digestion. The prepared libraries were size-selected, multiplexed and underwent quality control before paired-end sequencing. Reads were 75 base pairs in length. FASTQ data underwent quality control and were aligned to the hg19 genome using STAR 28 . Transcript quantification was performed using RSEM with default parameters 29 . TRACERx 100 RRBS. RRBS was obtained for approximately half of the NSCLC cohort with RNA-seq data (79 out of 164 tumour regions from 28 out of 64 patients, each with matched normal tissue). The NuGEN ovation RRBS methyl-seq system, adapted by the manufacturer for automation on an Agilent Bravo liquid handling robot, was used to generate sequencing libraries by enzymatically digesting 100 ng of gDNA using MspI, followed by adaptor ligation and the final repair step. Generated libraries were bisulfite-converted using the EpiTect Fast DNA Bisulfite Kit (Qiagen), PCR-amplified for 12 cycles and purified using Agencourt RNAClean XP magnetic beads. Purified libraries were quantified by Qubit double-strand DNA high-sensitivity assay (Invitrogen) and underwent quality control using Agilent Bioanalyzer high-sensitivity DNA Assay (Agilent Technologies). Eight samples were multiplexed per flow cell and sequenced on an Illumina HiSeq2500 system using HiSeq SBS kit v.4 in paired-end 100-bp runs for CRUK0062 and single-end 100-bp runs for the others, yielding on average 150 million raw sequencing reads per sample. Sequencing results were checked with FastQC v.0.11.2 (Babraham Institute, https://www.babraham.ac.uk/), adaptor sequences were trimmed with Trim Galore! V.0.3.7 (a wrapper around Cutadapt
30
) and NuGEN v.1.0 diversity trimming script (https://github.com/nugentechnologies/NuMetRRBS), and reads were aligned to the UCSC hg19 reference assembly using Bismark v.0.14.430. Read deduplication was carried out using NuDup (pre-release version, March 2015, https://github.com/nugentechnologies/nudup/), leveraging NuGEN's molecular tagging technology that produces on average 100 million unique reads per sample. Statistical information. All statistical tests were performed in R. No statistical methods were used to predetermine sample size. Tests involving correlations were done using 'cor.test' with the Spearman's method. Tests involving comparisons of distributions were done using 'wilcox.test' or 't.test' using the unpaired option, unless otherwise stated. Hazard ratios and P values were calculated with the 'survival' package. For all statistical tests, the number of data points included are plotted or annotated in the corresponding figure. Selection of immune-infiltration approach. Previously defined measures of immune infiltration and activity were used to classify the immune microenvironment of all tumours (and tumour regions) for which RNA-seq data were available 6-8, 12, 26 . The genes used in each one of the immune-estimation approaches were tested to see whether they fit two criteria: (1) having a negative relationship with tumour purity, as genes that define immune subtypes are expressed in infiltrating immune cells 8 and (2) not showing a positive correlation with tumour copy number at the gene locus (a positive correlation may indicate that the gene is expressed by the tumour cell, which would confound immune estimates). The proportion of genes in each immune-estimation method that passed these two criteria was compared. Finally, for each method, the immune estimates themselves were compared against independent ground-truth measures (pathology TIL estimates, flow cytometry quantification and T cell receptor abundance). The RNA-seq immune estimation that performed best in the TRACERx cohort was chosen. 11 closely, and performed nearly as well for the selection criteria.
The Jiang et al. 12 immune measures were calculated using the TIDE web interface (http://tide.dfci.harvard.edu/). Pathology TIL estimates. TILs were estimated from pathology slides using international established guidelines, developed by the International Immuno-Oncology Biomarker Working Group 27 . In brief, the relative proportion of stromal area to tumour area was determined from the pathology slide of a given tumour region. TILs were reported for the stromal compartment (= per cent stromal TILs). The denominator used to determine the per cent stromal TILs was the area of stromal tissue (that is, the area occupied by mononuclear inflammatory cells over total intratumoral stromal area) rather than the number of stromal cells (that is, the fraction of total stromal nuclei that represent mononuclear inflammatory cell nuclei). This method has been demonstrated to be reproducible among trained pathologists 31 . An inter-person concordance was performed, and this demonstrated high reproducibility. The International Immuno-Oncology Biomarker Working Group has developed a freely available training tool to train pathologists for optimal TIL assessment on haematoxylin-eosin slides (www.tilsincancer.org). Flow measurements. Tissue samples were collected and transported in RPMI-1640 (Sigma, cat. no. R0883-500ML). Single-cell suspensions were produced by enzymatic digestion using liberase, with subsequent cellular disaggregation using a Miltenyi gentleMACS Octo Dissociator. Lymphocytes were isolated from single-cell suspension by gradient centrifugation on Ficoll Paque Plus (GE Healthcare, cat. no. 17-1440-03) and stored in liquid nitrogen. Blood samples were collected in BD Vacutainer EDTA blood collection tubes (BD cat. no. 367525). Peripheral blood mononuclear cells were then isolated by gradient centrifugation on Ficoll Paque (GE Healthcare, cat. no. 17-1440-03), and stored in liquid nitrogen.
Fc receptors were blocked with human Fc receptor binding inhibitor (Thermo) before staining. Non-viable cells were stained using the eBioscience Fixable Viability Dye eFluor 780 (Thermo). Cells were stained in BD Brilliant stain buffer (BD cat. no. 563794) with the following monoclonal antibodies: anti-human CD3 (clone SK7, BD cat. no. 565511), anti-human CD4 (clone SK3, BD cat. no. 566003) and anti-human CD8 (clone RPA-T8, BD cat. no. 564804). Data were acquired on a BD Symphony flow cytometer and analysed in FlowJo. Cells were gated for size, single cells, live cells and CD3
+ T cells. T cell receptor abundance. A previously developed quantitative experimental and computational T cell receptor sequencing pipeline 32 was used for the high-throughput sequencing of α and β T cell receptor chains. T cell receptor sequencing was performed on whole RNA extracted from multi-region tumour specimens. A distinct feature of this T cell receptor sequencing protocol is the use of a unique molecular identifier that enables correction for PCR and sequencing errors, thereby providing a quantitative and reproducible method of library preparation 32, 33 . Classifying tumour regions as having high or low levels of immune infiltration. Tumours were split into either lung adenocarcinoma or lung squamous cell carcinoma. The Danaher et al. 11 estimates for all tumour regions from each histological type were clustered together using 'ward.D2' . The dendrogram was then cut into two. The samples that fell in the portion with higher estimates for levels of immune infiltrate were considered to be tumour regions with high levels of immune infiltration (immune high). Conversely, the samples that fell in the portion with lower estimates for levels of immune infiltrate were considered to be tumour regions with low levels of immune infiltration (immune low). If all tumour regions from a given sample were classified as immune low, that tumour was designated as uniformly immune low; if all tumour regions from a given sample were classified as immune high, that tumour was designated as uniformly immune high. If some tumour regions from the same tumour were immune high and others were immune low, the overall tumour classification was classified as 'heterogeneous' .
If a tumour region had no RNA-seq data available, it could be included in the analysis using the pathology TIL estimates. A tumour region was classified on the basis of pathology TIL estimates by determining whether the pathology TIL estimate for the tumour region in question was closer to the median of the pathology Article reSeArcH TIL estimates from the immune-high or immune-low tumour regions with RNA-seq data that had been clustered. The RNA-seq cohort (164 tumour regions from 64 TRACERx patients) was expanded by rescuing tumour regions that lacked accompanying RNA-seq data (Extended Data Fig. 2a ) with pathology TIL estimates (234 tumour regions from 83 TRACERx patients) (Extended Data  Fig. 4e ). Calculation of IPRES score. The calculation of the IPRES score was performed as previously described 13 . Distance measures. Immune distance. The immune distance was determined by taking the Euclidean distance of immune-infiltrate estimates between tumour regions. Genomic distance. The genomic distance was calculated by taking the Euclidean distance of the mutations present between tumour regions. All mutations present in any region from a tumour were turned into a binary matrix, in which the rows were mutations and the columns were tumour regions. This matrix was clustered, and the pairwise distance between any two tumour regions was determined. Calculation of Shannon diversity. For each tumour region, the Shannon diversity was estimated using the command 'entropy.empirical' from the 'entropy' R package. This was calculated on the basis of the number and prevalence of different tumour subclones found in that region, such that a tumour region that contained only one subclone was assigned a value of 0. The Shannon diversity score, H, followed the formula H = −Σp i × log(p i ), in which p i is the probability of the ith clone appearing in the tumour cell population. Predicted neoantigen binders. Novel 9-11mer peptides that could arise from identified non-silent mutations present in the sample 5 were determined. The predicted half-maximal inhibitory concentration binding affinities and rank percentage scores-representing the rank of the predicted affinity compared to a set of 400,000 random natural peptides-were calculated for all peptides that bound to each of the patient's HLA alleles using netMHCpan-2.8
17,34 and netMHC-4.0
34
. Using established thresholds, predicted binders were considered to be those peptides that had a predicted binding affinity < 500 nM or a rank percentage score < 2% by either tool. Strong predicted binders were those peptides that had a predicted binding affinity < 50 nM or rank percentage score < 0.5%. Of the 28,489 non-synonymous mutations in this cohort, 24,494 were predicted to encode peptides that were capable of binding to at least one of the patient's HLA class I alleles (binding affinity < 500 nM or rank percentage < 2) and 13,884 were predicted to strongly bind (binding affinity < 50 nM or rank percentage < 0.5) 17 . When RNA-seq data were available, a neoantigen was considered to be expressed if at least five RNA-seq reads mapped to the mutation position, and at least three contained the mutated base. Neoantigen depletion. Transcriptional depletion. Transcriptional neoantigen depletion was identified by first dividing tumours into immune classifications and HLA LOH categories (loss or no loss). All non-synonymous mutations were annotated as expressed in the RNA-seq data or not, using the definitions above. Then, a test for enrichment was performed to determine whether non-synonymous mutations that were neoantigens were less likely to be expressed than nonsynonymous mutations that were not predicted to be neoantigens. Copy-number depletion. Copy-number neoantigen depletion was identified by first dividing tumours into immune classifications. All non-synonymous mutations were annotated as either in a region of subclonal copy-number loss or not as identified in a previous report 5 . Then, a test for enrichment was performed to determine whether non-synonymous mutations that were neoantigens were more likely to be in regions of subclonal copy-number loss than were non-synonymous mutations that were not predicted to be neoantigens. Methylation. Neoantigens in genes that are consistently expressed across the TCGA NSCLC cohort were classified in two groups: expressed (in which the mutant is detected in at least 30 reads) and non-expressed (in which no mutant transcript is observed). Of the 375 non-expressed and 883 expressed neoantigens with matched RRBS data, 77 and 406 were unique, respectively (others were duplicates from different regions of the same patient). We down-sampled the expressed neoantigens list to match, as closely as possible, the gene expression and the variant allele frequency distributions that were observed for the non-expressed neoantigens. We then assessed differential methylation as follows: bulk and normal per-CpG methylation rates in promoters (2 kb up-and downstream of the transcription start site) modelled as beta distributions, B(α + 1, β + 1), in which α represents the observed methylated read counts and β represents the unmethylated read counts. We compute
tum n orm exactly, using We then apply Hochberg family-wise error rate correction, and flag promoters as hypermethylated when ≥3 CpGs are significantly hypermethylated (q < 0.05). Promoter counts are tested in a 2 × 2 contingency table (methylation status versus expression status or mutation status) using a χ 2 test. Depletion of neoantigens in expressed genes. Every mutated gene was first classified as consistently expressed or not consistently expressed in TCGA NSCLC. Genes were considered consistently expressed if they were expressed at ≥1 transcript per million in 95% of the TCGA samples for each histology. The expression classification of non-synonymous mutations that result in neoantigens was compared against the expression classification of non-synonymous mutations that do not result in neoantigens. A contingency table comparing neoantigenic to nonneoantigenic mutations, and whether they occurred in expressed or non-expressed genes, was obtained. Finally, using this contingency table, the odds ratio detailing the extent of neoantigen depletion in expressed genes was calculated using a Fisher's exact test. An odds ratio of <1 indicates that neoantigenic mutations were less likely to occur in consistently expressed genes than non-synonymous, non-neoantigenic mutations. Identifying tumour regions with HLA LOH. Tumour regions that contain an HLA LOH event were identified using a previously described method 20 .
Immune-evasion alterations. Antigen-presentation-pathway genes were compiled from a previous report 35 , and affected the HLA enhanceosome, peptide generation, chaperones or the MHC complex itself. They included disruptive events (nonsilent mutations or copy-number loss defined relative to ploidy 5 ) of the following genes: CIITA, IRF1, PSME1, PSME2, PSME3, ERAP1, ERAP2, HSPA (also known as PSMA7), HSPC (also known as HSPBP1), TAP1, TAP2, TAPBP, CALR, CNX (also known as CANX), PDIA3 and B2M. TCGA data. RNA-seq data were downloaded from the TCGA data portal. For each lung adenocarcinoma and lung squamous cell carcinoma, all available 'Level_3' gene-level data were obtained. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Code availability. All code used for analyses was written in R version 3.3.1 and is available at: https://bitbucket.org/snippets/raerose01/5enKR5.
Data availability
Sequence data used during the study has been deposited at the European Genomephenome Archive (EGA), which is hosted by The European Bioinformatics Institute (EBI) and the Centre for Genomic Regulation (CRG) under the accession codes: EGAS00001003458 (RNA-seq) and EGAS00001003484 (RRBS). Further information about EGA can be found at https://ega-archive.org. Any other relevant data can be obtained from the corresponding authors upon reasonable request. 
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Extended Data Fig. 1 | Determination of robust immune infiltration  approach. a-d, The expression of the genes used in each of the immunesignature definitions is correlated against tumour purity (a, b) and tumour copy number (c, d). Random genes (n = 1,000), or genes in the TIMER 8 (n = 575), EPIC 7 (n = 98), Danaher et al. 11 (n = 60), Rooney et al. 16 (n = 100) and Davoli et al. 6 (n = 75) immune-signature definitions, are plotted. The Spearman's ρ value of the correlation is plotted for the immune genes that comprise each signature definition, coloured by the P value of the association. The comparisons are performed separately for lung adenocarcinoma and lung squamous cell carcinoma. The median ρ value for the immune-signature set is indicated by the red line. The fraction of genes with an expression value that is significantly correlated with purity or tumour copy number is shown, and compared to a set of random genes. For every immune signature we considered, there was significant enrichment of genes with expression that was negatively correlated with tumour purity (as compared to the random selection of genes) and a significant enrichment of genes with expression that was positively correlated with tumour copy number (as compared to the random selection of genes + estimates from each of the immune-infiltration methods is shown (n = 140 tumour regions). Lung adenocarcinoma tumour regions are shown in blue; lung squamous cell carcinoma tumour regions are shown in red. Below, the top six correlations between pathology TIL estimates and an immune-cell subset is shown for each method. Blue boxes indicate positive correlation; red boxes indicate negative correlation. P values were corrected for false discovery rate. g, Example of CD8 T cell quantification in a representative TRACERx TIL sample. TILs were isolated from the tumour regions of surgical resections, as previously described 5 , and cryopreserved. Thawed samples were stained with a custom-designed 20-marker antibody panel to measure T cell activation, dysfunction and differentiation by flow cytometry. Fig. 6 | Relationship between immune infiltration and  tumour-region diversity. a, The pairwise copy number (cn) and immune distances between every two tumour regions from the same patient are compared for lung adenocarcinoma (n = 91) and lung squamous cell carcinoma (n = 60). b, c, For each tumour region, the CD8 + T cell score is plotted against the Shannon diversity score. Lung adenocarcinomas (n = 89) (b) and lung squamous cell carcinomas (n = 50) (c) are shown. d, The correlation between pathology TIL estimates and tumour purity is shown for lung adenocarcinoma (n = 120) (blue) and lung squamous cell carcinoma (n = 90) (red) regions. No relationship for either histology is observed. Spearman's test is used to determine the relationship. e, The Shannon diversity score per lung adenocarcinoma tumour region (n = 137) is plotted by immune classification, as determined solely by pathology TIL estimates. A two-sided Wilcoxon rank-sum test is used for comparison. f, A comparison of the observed:expected immunoediting score between lung adenocarcinoma and lung squamous cell carcinoma tumours (n = 92) is shown. A two-sided Wilcoxon rank-sum test is used for comparison. g, The observed:expected immunoediting score is shown by number of unique HLAs present in the tumour (patients heterozygous at HLA-A, HLA-B and HLA-C will have six unique HLA alleles) (n = 90). For all box plots, the minimum and maximum are indicated by the extreme points of the plot; the median is indicated by a thick horizontal line; and the first and third quartiles are indicated by box edges. h, The odds ratio and 95% confidence interval of transcriptional neoantigen depletion is shown for strongly binding neoantigens, calculated with Fisher's exact test. Values <1 indicate that putative neoantigens are less likely to be expressed, as compared to non-synonymous mutations that are not putative neoantigens. Tumours are broken down by HLA LOH status and their immune classification. i, The enrichment for neoantigens and strongly binding neoantigens to occur in non-expressed genes (as compared to non-synonymous non-neoantigens) is shown, calculated with Fisher's exact test. No corrections were made for multiple comparisons. 
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Extended Data Fig. 8 | Relationship between clonal neoantigen burden,  immune infiltration and patient prognosis. a, c, e , Kaplan-Meier curves are shown for lung adenocarcinoma and lung squamous cell carcinoma. The curves are split on the basis of the upper quartile of clonal neoantigen burden (a), on the upper quartile of subclonal neoantigen burden (c) and on the upper quartile of total neoantigen burden (e). For all survival curves, the number of patients in each group for every time point is indicated below the time point, and significance is determined using a log-rank test. b, d, The hazard ratio is shown for each threshold value of clonal neoantigen (b) and subclonal neoantigen (d) load, which indicates that a high clonal neoantigen burden remains significantly prognostic across a wide range of thresholds. Significant associations are indicated in red; non-significant associations are plotted in black. f, Clonal neoantigen load and immune-infiltration classification are incorporated in a multivariate analysis: this combination is more significant as a predictor of prognosis than either metric individually. Other tumour and clinical characteristics are also controlled for in the multivariate analysis. Hazard ratios of each variable with a 95% confidence interval are shown on the horizontal axis. Significance is calculated using a Cox proportional hazards model. All statistical tests were two-sided.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical methods were used to predetermine sample size. All patient tumor regions with RNA of sufficient quality (RIN score > 5) were included in this study. This represents the largest multi-region RNAseq immune profiling cohort and is sufficient for our exploratory analyses.
Data exclusions No data was excluded from analysis.
Replication
Findings were not replicated Randomization This is not relevant to the study, as samples were split on immune infiltration using hierarchical clustering.
Blinding
Blinding was not relevant to the study, as there was no control and treatment arms involved.
Reporting for specific materials, systems and methods 
Validation
Antibodies with prior manufacturer validation were used where possible, data is available at the manufacturer's website according to details in the methods section. Optibuild custom-conjugates were validated in house during panel development. To ensure robust staining we performed a series of experiments optimizing full panels on resting, and in vitro activated PBMC alongside a TIL sample with multiple vials available from the TRACERx 100 cohort. Consistency in machine performance was validated using compensation beads to check delta PMT values, by using an inter-run calibrating control (activated PBMC) and applying application settings.
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Human research participants Policy information about studies involving human research participants
Population characteristics
There were 68 male and 32 female non-small cell lung cancer patients in the TRACERx study, with a median age of 68. The cohort is predominantly early-stage: Ia(26), Ib(36), IIa(13), IIb(11), IIIa(13), IIIb(1). Seventy-two had no adjuvant treatment and 28 had adjuvant therapy. Patients were recruited into TRACERx according to the following eligibility criteria (taken from the study protocol). Inclusion criteria: -Written Informed consent -Patients ≥18 years of age, with early stage I-IIIA disease who are eligible for primary surgery -Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g. diagnosis determined from frozen section in theatre) -Primary surgery in keeping with NICE guidelines planned (see section 9.3) -Agreement to be followed up in a specialist centre -Performance status 0 or 1 -Suspected tumour at least 15mm in diameter on pre-operative imaging
Exclusion criteria: -Any other current malignancy or malignancy diagnosed or relapsed within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer) -Psychological condition that would preclude informed consent -Treatment with neo-adjuvant therapy for current lung malignancy deemed necessary -Adjuvant therapy other than platinum-based chemotherapy and/or radiotherapy -Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection.
-Sufficient tissue, i.e. a minimum of two tumour regions, is unlikely to be obtained for the study based on pre-operative imaging
Patient ineligibility following registration: -There is insufficient tissue -The patient is unable to comply with protocol requirements -There is a change in histology from NSCLC following surgery, or NSCLC is not confirmed during or after surgery.
-Change in staging to IIIB/IV following surgery -The operative criteria are not met (e.g. incomplete resection with macroscopic residual tumours (R2)); see section 9.3 for a list of accepted surgical procedures. Patients with microscopic residual tumours (R1) are eligible and should remain in the study -Adjuvant therapy other than platinum-based chemotherapy and/or radiotherapy is administered.
Recruitment
Patients seen with a new diagnosis of lung cancer in lung cancer units across the United Kingdom, according to the eligibility criteria above, were recruited. No selection bias has been identified to date. All patient tumor regions with RIN scores > 5 were used for RNA-sequencing and analyzed in this study. All patients were assigned a study ID that was known to the patient. These were subsequently converted to linked study Ids such that the patients could not identify themselves in study publications. All human samples, tissue and blood, were linked to the study ID and barcoded such that they were anonymised and tracked on a centralised database overseen by the study sponsor only.
Informed consent for entry into the TRACERx study was mandatory and obtained from every patient.
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The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
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Methodology Sample preparation
Single cell suspensions were obtained from surgically resected samples in the lung TRACERx study including multi-region tumor and normal adjacent tissue (enzymatic and mechanical digestion). PBMC (density gradient centrifugation) were obtained from blood draws. All samples were cryopreserved until the point of use.
Instrument
Data was acquired on a BD Symphony (analyzer) or BD FACS ARIAII (sorting)
Software
Treestar FLOWJO v 10 (manual gating)
Cell population abundance Post sort purity was determined by re-acquiring an aliquot of sorted sample, following acquisition of a blank tube. All samples were >98% purity.
Gating strategy 
